February 3, 2023
ISOFOL INVITES SHAREHOLDERS TO AN
EXTRAORDINARY GENERAL MEETING ON FEBRUARY 28, 2023
January 19, 2023
ISOFOL INVITES SHAREHOLDERS TO AN
EXTRAORDINARY GENERAL MEETING ON FEBRUARY 13, 2023
This website is intended for use by residents of Sweden only
About Isofol
Isofol Medical AB (publ) is a biotech company that was founded in 2008 and is developing a new drug candidate for the treatment of advanced colorectal cancer. Colorectal cancer (CRC) is the third most common form of cancer worldwide and the need for more effective drugs to treat this disease is very high.
Upcoming Events
- February 13, 2023 - February 13, 2023
Extraordinary General Meeting, February 13, 2023 - February 22, 2023 - February 22, 2023
Year-end Report 2022 - February 28, 2023 - February 28, 2023
Extraordinary General Meeting, February 28, 2023
Media – Lates pressreleases
Isofol has obtained a request to call for an extraordinary general meeting
GOTHENBURG, Sweden, January 30, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained a request to call an extraordinary general meeting to…
Isofol invites to an informational meeting on January 30 prior to extraordinary general meeting
GOTHENBURG, Sweden, January 20, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), yesterday called shareholders to an extraordinary general meeting on February…
Notice convening the extraordinary general meeting in Isofol Medical AB (publ) 13 February 2023
GOTHENBURG, Sweden, January 19, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No….
INVESTORS – Latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
